We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third‐line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
- Authors
Li, Chuanming; Yu, Fan; Xu, Wanli
- Abstract
What Is Known and Objective: Programmed cell death protein‐1 (PD‐1) inhibitors synergize apatinib for anti‐tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This study aimed to investigate the treatment efficacy and safety of camrelizumab (PD‐1 inhibitor) plus apatinib as third‐line or above therapy in metastatic colorectal cancer (mCRC) patients. Methods: Totally, 64 unresectable mCRC patients receiving camrelizumab plus apatinib (N = 31) and apatinib (N = 33) were retrospectively enrolled. Results: Disease control rate (80.6% vs. 57.6%) (P = 0.047) was elevated in camrelizumab plus apatinib group compared to apatinib group; however, objective response rate (22.6% vs. 6.1%) (P = 0.078) only showed an increasing trend but did not achieve statistical significance. Besides, the median (95% confidence interval [CI]) progressive‐free survival (PFS) and overall survival (OS) were 6.9 (3.7–10.1) and 11.5 (7.7–15.3) months in camrelizumab plus apatinib group; meanwhile, the median (95% CI) PFS and OS were 3.6 (1.7–5.5) and 6.7 (5.0–8.4) months in the apatinib group. Additionally, PFS (P = 0.017) and OS (P = 0.006) were prolonged in camrelizumab plus apatinib group compared with apatinib group, which was confirmed by further multivariate Cox's proportional hazards regression analysis (hazard ratio [HR] = 0.340, P < 0.001 for PFS; HR = 0.271, P < 0.001 for OS). The incidence of total, grade 1–2, and grade 3–4 adverse events did not differ between groups (all P > 0.05). Conclusion: Camrelizumab (PD‐1 inhibitor) plus apatinib achieves a better treatment efficacy than apatinib as third‐line or above therapy with a good safety profile in mCRC patients.
- Subjects
THERAPEUTIC use of monoclonal antibodies; DRUG efficacy; COMBINATION drug therapy; CONFIDENCE intervals; MULTIVARIATE analysis; METASTASIS; RETROSPECTIVE studies; REGRESSION analysis; PROTEIN-tyrosine kinase inhibitors; COLORECTAL cancer; CANCER patients; COMPARATIVE studies; TREATMENT effectiveness; DESCRIPTIVE statistics; PROGRESSION-free survival; DATA analysis software; PATIENT safety; LONGITUDINAL method; PROPORTIONAL hazards models
- Publication
Journal of Clinical Pharmacy & Therapeutics, 2022, Vol 47, Issue 12, p2325
- ISSN
0269-4727
- Publication type
Article
- DOI
10.1111/jcpt.13803